Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans
MONTREAL, June 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today the successful syndication of $600 million of incremental term loans under its existing senior secured credit facilities to be used to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions. The incremental term loans will mature in 2019 and have terms that are similar to the Company's existing $600 million Term Loan B facility, with certain modifications. The facility closed on June 14, 2012.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
Laurie W. Little
SOURCE Valeant Pharmaceuticals International, Inc.